COVID-19 drugs: A necessary strategy for living with COVID-19 in the new normal and the mutations of the SARS-CoV-2 such as omicron variant

Q3 Biochemistry, Genetics and Molecular Biology
Dinh chu, N. Bui, Yen Thi, Suong Ngoc
{"title":"COVID-19 drugs: A necessary strategy for living with COVID-19 in the new normal and the mutations of the SARS-CoV-2 such as omicron variant","authors":"Dinh chu, N. Bui, Yen Thi, Suong Ngoc","doi":"10.5455/jabet.2022.d111","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine developmentICLE witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant. © 2022, Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. All rights reserved.","PeriodicalId":36275,"journal":{"name":"Journal of Advanced Biotechnology and Experimental Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advanced Biotechnology and Experimental Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/jabet.2022.d111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

The COVID-19 pandemic has spread rapidly and caused significant damage to global public health as well as the economy. While the race of vaccine developmentICLE witnessed a spectacular breakthrough with the introduction of highly effective vaccines such as BNT162b2, mRNA-1273, or AZD1222, no specific drug for COVID-19 treatment has been discovered yet. Recently, repurposing drugs classified into three main groups of mechanisms, including antivirus, anti-SARS-CoV-2 antibodies, and immunomodulators, are investigated. As a result, Remdesivir and six other drugs are authorized by the Food and Drug Administration (FDA) to treat patients infected by the SARS-CoV-2. This work aims to highlight that, besides vaccines, COVID-19 drugs should get more attention and be considered as one of the most promising strategies to safely coexist with the SARS-CoV-2 virus in the new normal status and for the mutations of the virus, such as the omicron variant. © 2022, Bangladesh Society for Microbiology, Immunology and Advanced Biotechnology. All rights reserved.
COVID-19药物:新常态和SARS-CoV-2组粒变异等突变下生存的必要策略
新冠肺炎疫情迅速蔓延,对全球公共卫生和经济造成重大损害。虽然随着BNT162b2、mRNA-1273、AZD1222等高效疫苗的问世,疫苗开发竞赛取得了惊人的突破,但目前还没有发现针对COVID-19的特异性药物。最近,对药物再利用的研究主要分为三大类机制,包括抗病毒药物、抗sars - cov -2抗体和免疫调节剂。因此,Remdesivir和其他六种药物被美国食品和药物管理局(FDA)批准用于治疗感染SARS-CoV-2的患者。这项工作旨在强调,除了疫苗,COVID-19药物应该得到更多的关注,并被认为是在新常态下与SARS-CoV-2病毒安全共存的最有希望的策略之一,以及病毒的突变,如组粒变异。©2022,孟加拉国微生物学、免疫学和先进生物技术学会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Advanced Biotechnology and Experimental Therapeutics
Journal of Advanced Biotechnology and Experimental Therapeutics Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
1.90
自引率
0.00%
发文量
41
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信